Tag: CPT codes for COVID vaccines

AMA Updates COVID-19 Vaccine CPT Codes

The American Medical Association (AMA) today announced that the Current Procedural Terminology (CPT) code set has been updated by the CPT Editorial Panel to include vaccine and administration codes that are unique to a new formulation of the COVID-19 vaccine developed by Pfizer. The new formulation is based on a tris-sucrose buffer rather than the phosphate buffer present in the original formulation.

The provisional CPT codes will be effective for use on the condition that tris-sucrose formulation of Pfizer’s COVID-19 vaccine receives approval or emergency use authorization from the U.S. Food and Drug Administration (FDA). The AMA is publishing the CPT code update now to ensure electronic systems across the U.S. health care system are prepared in advance for the potential FDA approval or authorization of the tris-sucrose formulation of Pfizer’s COVID-19 vaccine.

The development of vaccine-specific CPT codes has clinically distinguished each coronavirus vaccine and dosing schedule for better tracking, reporting and analysis that supports data-driven planning and allocation. COVID-19 vaccines from AstraZeneca, Janssen (Johnson & Johnson), Moderna, Novavax and Pfizer’s original formulation have previously been issued unique CPT codes.

To help ensure accurate coding and reporting of COVID-19 vaccines and immunization services, the AMA offers a vaccine code finder resource to help identify the appropriate CPT code combination for the type and dose of COVID-19 vaccine provided to each patient.

For quick reference, the new vaccine and administration codes assigned to the tris-sucrose formulation of Pfizer’s COVID-19 vaccine are:

Continue Reading